CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Gilteritinib (Xospata) for Acute Myeloid Leukemia 
(Final Recommendation Issued as of May 20, 2020)

Atezolizumab (Tecentriq) & Bevacizumab (Avastin) for Hepatocellular Carcinoma
(Open for Input on Submission until June 4, 2020)

Sonidegib (Odomzo) for Basal Cell Carcinoma
(Pending Submission as of May 15, 2020)

Nivolumab (Opdivo) in combo with Ipilimumab (Yervoy) for Non-Small Cell Lung Cancer
(Pending Submission as of May 26, 2020)



Find a Drug Review